false2022Q20001549084--12-3191P5DP5Dfive years, six months5.500015490842022-01-012022-06-3000015490842022-07-26xbrli:shares00015490842022-06-30iso4217:USD00015490842021-12-31iso4217:USDxbrli:shares00015490842022-04-012022-06-3000015490842021-04-012021-06-3000015490842021-01-012021-06-300001549084us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2021-12-310001549084us-gaap:CommonStockMember2021-12-310001549084us-gaap:AdditionalPaidInCapitalMember2021-12-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001549084us-gaap:RetainedEarningsMember2021-12-310001549084us-gaap:RetainedEarningsMember2022-01-012022-03-3100015490842022-01-012022-03-310001549084us-gaap:CommonStockMember2022-01-012022-03-310001549084us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001549084us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2022-03-310001549084us-gaap:CommonStockMember2022-03-310001549084us-gaap:AdditionalPaidInCapitalMember2022-03-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001549084us-gaap:RetainedEarningsMember2022-03-3100015490842022-03-310001549084us-gaap:RetainedEarningsMember2022-04-012022-06-300001549084us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001549084us-gaap:CommonStockMember2022-06-300001549084us-gaap:AdditionalPaidInCapitalMember2022-06-300001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001549084us-gaap:RetainedEarningsMember2022-06-300001549084us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2020-12-310001549084us-gaap:CommonStockMember2020-12-310001549084us-gaap:AdditionalPaidInCapitalMember2020-12-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001549084us-gaap:RetainedEarningsMember2020-12-3100015490842020-12-310001549084us-gaap:RetainedEarningsMember2021-01-012021-03-3100015490842021-01-012021-03-310001549084us-gaap:CommonStockMember2021-01-012021-03-310001549084us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001549084us-gaap:PreferredStockMemberus-gaap:ConvertiblePreferredStockMember2021-03-310001549084us-gaap:CommonStockMember2021-03-310001549084us-gaap:AdditionalPaidInCapitalMember2021-03-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001549084us-gaap:RetainedEarningsMember2021-03-3100015490842021-03-310001549084us-gaap:RetainedEarningsMember2021-04-012021-06-300001549084us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001549084us-gaap:CommonStockMember2021-06-300001549084us-gaap:AdditionalPaidInCapitalMember2021-06-300001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001549084us-gaap:RetainedEarningsMember2021-06-3000015490842021-06-300001549084us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-06-30ekso:customer0001549084us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-03-310001549084us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-06-300001549084us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberekso:CustomerAMember2022-01-012022-06-30xbrli:pure0001549084us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-04-012021-06-300001549084us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberekso:CustomerAMember2021-01-012021-06-300001549084us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001549084us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001549084us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300001549084us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300001549084us-gaap:FairValueMeasurementsRecurringMember2022-06-300001549084us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-06-300001549084us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-06-300001549084us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001549084us-gaap:FairValueMeasurementsRecurringMember2021-12-310001549084us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001549084us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310001549084us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001549084us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-12-310001549084us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-06-300001549084srt:MinimumMemberekso:EksoHealthMember2022-01-012022-06-300001549084srt:MaximumMemberekso:EksoHealthMember2022-01-012022-06-3000015490842022-04-012022-06-3000015490842023-01-012022-06-3000015490842024-01-012022-06-300001549084us-gaap:RoyaltyMember2022-01-012022-06-300001549084ekso:AccountsReceivableNetAndOtherAssetsMember2022-06-300001549084ekso:AccountsReceivableNetAndOtherAssetsMember2021-12-310001549084srt:MinimumMember2022-01-012022-06-300001549084srt:MaximumMember2022-01-012022-06-300001549084us-gaap:ProductMemberekso:EksoHealthMember2022-01-012022-06-300001549084us-gaap:ProductMemberekso:EksoWorksMember2022-01-012022-06-300001549084us-gaap:ProductMember2022-01-012022-06-300001549084ekso:EksoHealthMemberus-gaap:ServiceMember2022-01-012022-06-300001549084ekso:EksoWorksMemberus-gaap:ServiceMember2022-01-012022-06-300001549084us-gaap:ServiceMember2022-01-012022-06-300001549084ekso:SubscriptionsMemberekso:EksoHealthMember2022-01-012022-06-300001549084ekso:SubscriptionsMemberekso:EksoWorksMember2022-01-012022-06-300001549084ekso:SubscriptionsMember2022-01-012022-06-300001549084us-gaap:ProductAndServiceOtherMemberekso:EksoHealthMember2022-01-012022-06-300001549084ekso:EksoWorksMemberus-gaap:ProductAndServiceOtherMember2022-01-012022-06-300001549084us-gaap:ProductAndServiceOtherMember2022-01-012022-06-300001549084ekso:CollaborativeArrangementsMemberekso:EksoHealthMember2022-01-012022-06-300001549084ekso:EksoWorksMemberekso:CollaborativeArrangementsMember2022-01-012022-06-300001549084ekso:CollaborativeArrangementsMember2022-01-012022-06-300001549084ekso:EksoHealthMember2022-01-012022-06-300001549084ekso:EksoWorksMember2022-01-012022-06-300001549084us-gaap:ProductMemberekso:EksoHealthMember2021-01-012021-06-300001549084us-gaap:ProductMemberekso:EksoWorksMember2021-01-012021-06-300001549084us-gaap:ProductMember2021-01-012021-06-300001549084ekso:EksoHealthMemberus-gaap:ServiceMember2021-01-012021-06-300001549084ekso:EksoWorksMemberus-gaap:ServiceMember2021-01-012021-06-300001549084us-gaap:ServiceMember2021-01-012021-06-300001549084ekso:RentalsAndSubscriptionsMemberekso:EksoHealthMember2021-01-012021-06-300001549084ekso:EksoWorksMemberekso:RentalsAndSubscriptionsMember2021-01-012021-06-300001549084ekso:RentalsAndSubscriptionsMember2021-01-012021-06-300001549084us-gaap:ProductAndServiceOtherMemberekso:EksoHealthMember2021-01-012021-06-300001549084ekso:EksoWorksMemberus-gaap:ProductAndServiceOtherMember2021-01-012021-06-300001549084us-gaap:ProductAndServiceOtherMember2021-01-012021-06-300001549084ekso:CollaborativeArrangementsMemberekso:EksoHealthMember2021-01-012021-06-300001549084ekso:EksoWorksMemberekso:CollaborativeArrangementsMember2021-01-012021-06-300001549084ekso:CollaborativeArrangementsMember2021-01-012021-06-300001549084ekso:EksoHealthMember2021-01-012021-06-300001549084ekso:EksoWorksMember2021-01-012021-06-300001549084ekso:WarrantyMember2022-03-310001549084ekso:WarrantyMember2021-12-310001549084ekso:WarrantyMember2022-04-012022-06-300001549084ekso:WarrantyMember2022-01-012022-06-300001549084ekso:WarrantyMember2022-06-300001549084ekso:WarrantyMember2021-06-300001549084ekso:PWBLoanAgreementMemberekso:TermLoanMember2020-08-310001549084ekso:PWBLoanAgreementMemberekso:TermLoanMemberus-gaap:PrimeRateMember2020-08-012020-08-300001549084ekso:PWBLoanAgreementMemberekso:TermLoanMember2022-06-300001549084ekso:PWBLoanAgreementMemberekso:TermLoanMember2022-01-012022-06-300001549084us-gaap:UnsecuredDebtMember2020-04-200001549084us-gaap:UnsecuredDebtMember2020-04-202020-04-200001549084us-gaap:UnsecuredDebtMember2021-06-282021-06-280001549084ekso:RichmondCaliforniaMember2022-06-300001549084ekso:HamburgGermanyMember2022-06-300001549084ekso:HamburgGermanyMember2022-02-28ekso:extension0001549084ekso:February2021OfferingMemberus-gaap:OverAllotmentOptionMember2021-01-012021-02-280001549084ekso:February2021OfferingMemberus-gaap:OverAllotmentOptionMember2021-02-280001549084ekso:February2021OfferingMember2021-01-012021-02-280001549084ekso:A2021WarrantsMember2021-02-280001549084ekso:February2021OfferingMember2021-02-280001549084ekso:AtTheMarketOfferingMember2020-10-012020-10-290001549084ekso:AtTheMarketOfferingMember2020-10-290001549084ekso:AtTheMarketOfferingMember2022-04-012022-06-300001549084us-gaap:CommonStockMemberekso:AtTheMarketOfferingMember2022-01-012022-06-300001549084ekso:A2021WarrantsMember2022-06-300001549084ekso:A2021WarrantsMember2022-01-012022-06-300001549084ekso:June2020InvestorWarrantsMember2022-06-300001549084ekso:June2020InvestorWarrantsMember2022-01-012022-06-300001549084ekso:June2020InvestorWarrantsMember2021-12-310001549084ekso:June2020PlacementAgentWarrantsMember2020-09-300001549084ekso:June2020PlacementAgentWarrantsMember2022-01-012022-06-300001549084ekso:June2020PlacementAgentWarrantsMember2021-12-310001549084ekso:June2020PlacementAgentWarrantsMember2022-06-300001549084ekso:December2019WarrantsMember2022-06-300001549084ekso:December2019WarrantsMember2022-01-012022-06-300001549084ekso:December2019WarrantsMember2021-12-310001549084ekso:December2019PlacementAgentWarrantsMember2022-06-300001549084ekso:December2019PlacementAgentWarrantsMember2022-01-012022-06-300001549084ekso:December2019PlacementAgentWarrantsMember2021-12-310001549084ekso:May2019WarrantsMember2022-06-300001549084ekso:May2019WarrantsMember2022-01-012022-06-300001549084ekso:May2019WarrantsMember2021-12-310001549084us-gaap:CommonStockMember2021-01-012021-06-300001549084us-gaap:CommonStockMember2022-04-012022-06-300001549084ekso:A2021WarrantsMember2021-01-012021-02-280001549084us-gaap:MeasurementInputSharePriceMemberekso:A2021WarrantsMember2022-06-300001549084us-gaap:MeasurementInputSharePriceMemberekso:A2021WarrantsMember2021-12-310001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-06-300001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-03-310001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:A2021WarrantsMember2022-06-300001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:A2021WarrantsMember2021-12-310001549084us-gaap:MeasurementInputExpectedTermMemberekso:A2021WarrantsMember2022-06-300001549084us-gaap:MeasurementInputExpectedTermMemberekso:A2021WarrantsMember2021-12-310001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2022-06-300001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-12-310001549084ekso:June2020InvestorWarrantsMember2020-06-300001549084ekso:June2020InvestorWarrantsMember2020-09-300001549084ekso:June2020InvestorWarrantsMember2021-01-012021-06-300001549084ekso:June2020InvestorWarrantsMember2020-06-012020-06-300001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputSharePriceMember2022-06-300001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputSharePriceMember2021-12-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-06-300001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-03-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-06-300001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2022-06-300001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-12-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2022-06-300001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-12-310001549084ekso:June2020PlacementAgentWarrantsMember2020-06-012020-06-300001549084ekso:June2020PlacementAgentWarrantsMember2021-01-012021-06-300001549084us-gaap:MeasurementInputSharePriceMemberekso:June2020PlacementAgentWarrantsMember2022-06-300001549084us-gaap:MeasurementInputSharePriceMemberekso:June2020PlacementAgentWarrantsMember2021-12-310001549084ekso:June2020PlacementAgentWarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-06-300001549084ekso:June2020PlacementAgentWarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-03-310001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:June2020PlacementAgentWarrantsMember2022-06-300001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:June2020PlacementAgentWarrantsMember2021-12-310001549084us-gaap:MeasurementInputExpectedTermMemberekso:June2020PlacementAgentWarrantsMember2022-06-300001549084us-gaap:MeasurementInputExpectedTermMemberekso:June2020PlacementAgentWarrantsMember2021-12-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:June2020PlacementAgentWarrantsMember2022-06-300001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:June2020PlacementAgentWarrantsMember2021-12-310001549084ekso:December2019WarrantsMember2019-12-310001549084ekso:December2019WarrantsMember2019-12-012019-12-310001549084us-gaap:MeasurementInputSharePriceMemberekso:December2019WarrantsMember2022-06-300001549084us-gaap:MeasurementInputSharePriceMemberekso:December2019WarrantsMember2021-12-310001549084ekso:December2019WarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-06-300001549084ekso:December2019WarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-03-310001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:December2019WarrantsMember2022-06-300001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:December2019WarrantsMember2021-12-310001549084us-gaap:MeasurementInputExpectedTermMemberekso:December2019WarrantsMember2022-06-300001549084us-gaap:MeasurementInputExpectedTermMemberekso:December2019WarrantsMember2021-12-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:December2019WarrantsMember2022-06-300001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:December2019WarrantsMember2021-12-310001549084ekso:December2019PlacementAgentWarrantsMember2019-12-310001549084us-gaap:MeasurementInputSharePriceMemberekso:December2019PlacementAgentWarrantsMember2022-06-300001549084us-gaap:MeasurementInputSharePriceMemberekso:December2019PlacementAgentWarrantsMember2021-12-310001549084ekso:December2019PlacementAgentWarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-06-300001549084ekso:December2019PlacementAgentWarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-03-310001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:December2019PlacementAgentWarrantsMember2022-06-300001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:December2019PlacementAgentWarrantsMember2021-12-310001549084us-gaap:MeasurementInputExpectedTermMemberekso:December2019PlacementAgentWarrantsMember2022-06-300001549084us-gaap:MeasurementInputExpectedTermMemberekso:December2019PlacementAgentWarrantsMember2021-12-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:December2019PlacementAgentWarrantsMember2022-06-300001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:December2019PlacementAgentWarrantsMember2021-12-310001549084ekso:May2019WarrantsMember2019-05-310001549084ekso:May2019WarrantsMember2020-09-300001549084ekso:May2019WarrantsMemberus-gaap:CommonStockMemberekso:DirectOfferingMember2020-09-300001549084ekso:June2020WarrantsMember2020-09-300001549084ekso:May2019WarrantsMember2021-01-012021-06-300001549084ekso:May2019WarrantsMember2019-05-012019-05-300001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputSharePriceMember2022-06-300001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputSharePriceMember2021-12-310001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-06-300001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputConversionPriceMember2022-01-012022-03-310001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-06-300001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2022-06-300001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-12-310001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2022-06-300001549084ekso:May2019WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-12-310001549084ekso:June2020WarrantsMember2022-01-012022-06-300001549084ekso:EquityIncentivePlan2014Member2022-06-300001549084ekso:EquityIncentivePlan2014Member2021-12-310001549084ekso:EquityIncentivePlan2014Member2022-01-012022-06-300001549084ekso:EquityIncentivePlan2014Member2022-06-300001549084us-gaap:EmployeeStockOptionMember2022-06-300001549084us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001549084us-gaap:RestrictedStockUnitsRSUMember2022-06-300001549084us-gaap:RestrictedStockUnitsRSUMember2021-12-310001549084us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001549084us-gaap:SellingAndMarketingExpenseMember2022-04-012022-06-300001549084us-gaap:SellingAndMarketingExpenseMember2021-04-012021-06-300001549084us-gaap:SellingAndMarketingExpenseMember2022-01-012022-06-300001549084us-gaap:SellingAndMarketingExpenseMember2021-01-012021-06-300001549084us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001549084us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001549084us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001549084us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001549084us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001549084us-gaap:GeneralAndAdministrativeExpenseMember2021-04-012021-06-300001549084us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001549084us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-06-300001549084us-gaap:RoyaltyAgreementTermsMember2022-06-30ekso:license_agreement0001549084us-gaap:RoyaltyAgreementTermsMemberekso:SalesRevenueGoodsNetExcludingGovernmentSalesMember2022-01-012022-06-300001549084us-gaap:RoyaltyAgreementTermsMemberekso:LicenseRevenueMember2022-01-012022-06-300001549084us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001549084us-gaap:EmployeeStockOptionMember2021-04-012021-06-300001549084us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001549084us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001549084us-gaap:RestrictedStockMember2022-04-012022-06-300001549084us-gaap:RestrictedStockMember2021-04-012021-06-300001549084us-gaap:RestrictedStockMember2022-01-012022-06-300001549084us-gaap:RestrictedStockMember2021-01-012021-06-300001549084us-gaap:WarrantMember2022-04-012022-06-300001549084us-gaap:WarrantMember2021-04-012021-06-300001549084us-gaap:WarrantMember2022-01-012022-06-300001549084us-gaap:WarrantMember2021-01-012021-06-30ekso:segment0001549084ekso:EksoHealthMember2022-04-012022-06-300001549084ekso:EksoWorksMember2022-04-012022-06-300001549084ekso:EksoHealthMember2021-04-012021-06-300001549084ekso:EksoWorksMember2021-04-012021-06-300001549084country:US2022-04-012022-06-300001549084country:US2021-04-012021-06-300001549084country:US2022-01-012022-06-300001549084country:US2021-01-012021-06-300001549084ekso:AmericasOtherMember2022-04-012022-06-300001549084ekso:AmericasOtherMember2021-04-012021-06-300001549084ekso:AmericasOtherMember2022-01-012022-06-300001549084ekso:AmericasOtherMember2021-01-012021-06-300001549084srt:AmericasMember2022-04-012022-06-300001549084srt:AmericasMember2021-04-012021-06-300001549084srt:AmericasMember2022-01-012022-06-300001549084srt:AmericasMember2021-01-012021-06-300001549084country:DE2022-04-012022-06-300001549084country:DE2021-04-012021-06-300001549084country:DE2022-01-012022-06-300001549084country:DE2021-01-012021-06-300001549084country:BE2022-04-012022-06-300001549084country:BE2021-04-012021-06-300001549084country:BE2022-01-012022-06-300001549084country:BE2021-01-012021-06-300001549084ekso:EMEAOtherMember2022-04-012022-06-300001549084ekso:EMEAOtherMember2021-04-012021-06-300001549084ekso:EMEAOtherMember2022-01-012022-06-300001549084ekso:EMEAOtherMember2021-01-012021-06-300001549084us-gaap:EMEAMember2022-04-012022-06-300001549084us-gaap:EMEAMember2021-04-012021-06-300001549084us-gaap:EMEAMember2022-01-012022-06-300001549084us-gaap:EMEAMember2021-01-012021-06-300001549084country:JP2022-01-012022-06-300001549084country:JP2021-01-012021-06-300001549084ekso:APACOtherMember2022-01-012022-06-300001549084ekso:APACOtherMember2021-01-012021-06-300001549084srt:AsiaPacificMember2022-04-012022-06-300001549084srt:AsiaPacificMember2021-04-012021-06-300001549084srt:AsiaPacificMember2022-01-012022-06-300001549084srt:AsiaPacificMember2021-01-012021-06-30
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________________________________________ 
FORM 10-Q 
____________________________________________________________________________________________
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______ 
Commission File Number: 001-37854 
____________________________________________________________________________________________ 
Ekso Bionics Holdings, Inc.

(Exact name of registrant as specified in its charter) 
____________________________________________________________________________________________
Nevada 99-0367049
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification No.)
 
1414 Harbour Way SouthSuite 1201
RichmondCA
 94804
(Address of principal executive offices) (Zip Code)
 
(510) 984-1761
(Registrant’s telephone number, including area code)
________________________________
(Former name, former address, and former fiscal year, if changed since last report)
____________________________________________________________________________________________

Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Name of each exchange on which registered:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareEKSO
Nasdaq Capital Market


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x    No ¨
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x     No ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer
   
Non-accelerated filer Smaller reporting company
  
Emerging growth company 
 


Table of Contents


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act   
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No x
 
The number of shares of registrant’s common stock outstanding as of July 26, 2022 was 13,026,620.



Table of Contents
 Ekso Bionics Holdings, Inc.
 
Quarterly Report on Form 10-Q 

Table of Contents
  
 Page No.
  
   
   
 
   
 
   
 
   
 
   
   
   
   
  
   
   
   
 



Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
 

Ekso Bionics Holdings, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except par value)
 
 June 30, 2022December 31, 2021
 (unaudited)(Note 2)
Assets  
Current assets:  
Cash$31,912 $40,406 
Accounts receivable, net of allowances of $21 and $28, respectively
3,341 4,662 
Inventories3,274 2,242 
Prepaid expenses and other current assets796 485 
Total current assets39,323 47,795 
Property and equipment, net905 991 
Right-of-use assets164 216 
Other assets128 164 
Total assets$40,520 $49,166 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$2,045 $3,107 
Accrued liabilities1,583 2,299 
Deferred revenues, current1,140 1,220 
Lease liabilities, current51 229 
Total current liabilities4,819 6,855 
Deferred revenues1,143 1,475 
Note payable, net1,995 1,993 
Lease liability114  
Warrant liabilities651 1,550 
Other non-current liabilities69 74 
Total liabilities8,791 11,947 
Commitments and contingencies (Note 13)
Stockholders’ equity:
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding at June 30, 2022 and December 31, 2021
  
Common stock, $0.001 par value; 141,429 shares authorized; 13,010 and 12,693 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively
13 13 
Additional paid-in capital247,347 246,090 
Accumulated other comprehensive gain (loss)834 (17)
Accumulated deficit(216,465)(208,867)
Total stockholders’ equity31,729 37,219 
Total liabilities and stockholders’ equity$40,520 $49,166 
 

The accompanying notes are an integral part of these condensed consolidated financial statements


Table of Contents
Ekso Bionics Holdings, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)
 
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Revenue$3,465 $2,211 $6,032 $4,121 
Cost of revenue1,824 919 3,182 1,594 
Gross profit1,641 1,292 2,850 2,527 
Operating expenses:
Sales and marketing1,841 1,787 3,470 3,580 
Research and development920 709 1,919 1,312 
General and administrative2,109 2,144 4,927 4,122 
Total operating expenses4,870 4,640 10,316 9,014 
Loss from operations(3,229)(3,348)(7,466)(6,487)
Other income (expense), net:
Interest expense(29)(27)(56)(53)
Gain on revaluation of warrant liabilities999 875 899 886 
Gain on forgiveness of note payable 1,099  1,099 
Unrealized (loss) gain on foreign exchange(718)131 (972)(372)
Other expense, net(1)(3)(3)(16)
Total other income (expense), net251 2,075 (132)1,544 
Net loss$(2,978)$(1,273)$(7,598)$(4,943)
Other comprehensive income (loss)639 (125)851 340 
Comprehensive loss$(2,339)$(1,398)$(6,747)$(4,603)
Net loss per share applicable to common shareholders, basic$(0.23)$(0.10)$(0.59)$(0.42)
Net loss per share applicable to common shareholders, diluted$(0.23)$(0.11)$(0.59)$(0.44)
Weighted average number of shares outstanding, basic12,884 12,655 12,807 11,709 
Weighted average number of shares outstanding, diluted12,884 12,737 12,807 11,839 
 
The accompanying notes are an integral part of these condensed consolidated financial statements


Table of Contents
Ekso Bionics Holdings, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands)
(Unaudited)
Convertible Preferred StockCommon StockAdditional Paid-in CapitalAccumulated Other Comprehensive
(Loss) Income
Accumulated DeficitTotal Stockholders’
 Equity
SharesAmountSharesAmount
Balance at December 31, 2021 $ 12,693 $13 $246,090 $(17)$(208,867)$37,219 
Net loss— — — — — — (4,620)(4,620)
Issuance of common stock under:
Matching contribution to 401(k) plan— — 68 — 176 — — 176 
Equity incentive plan— — 83 — — — — — 
Stock-based compensation expense— — — — 499 — — 499 
Foreign currency translation adjustments— — — — — 212 — 212 
Balance at March 31, 2022 $ 12,844 $13 $246,765 $195 $(213,487)$33,486 
Net loss— — — — — — (2,978)(2,978)
Issuance of common stock under:
Equity incentive plan— — 166 — — — — — 
Stock-based compensation expense— — — — 582 — — 582 
Foreign currency translation adjustments— — — — — 639 — 639 
Balance at June 30, 2022— $— 13,010 $13 $247,347 $834 $(216,465)$31,729 



















Table of Contents
Ekso Bionics Holdings, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands)
(Unaudited)

Convertible Preferred StockCommon StockAdditional Paid-in CapitalAccumulated Other Comprehensive (Loss) IncomeAccumulated DeficitTotal Stockholders’ Equity
SharesAmountSharesAmount
Balance at December 31, 2020 $ 8,349 $8 $204,376 $(847)$(199,103)$4,434 
Net loss— — — — — — (3,670)(3,670)
Issuance of common stock under:
Equity financing, net— — 3,980 4 35,356 — — 35,360 
Exercise of warrants— — 300 1 3,877 — — 3,878 
Matching contribution to 401(k) plan— — 26 — 152 — — 152 
Stock-based compensation expense— — — — 356 — — 356 
Foreign currency translation adjustments— — — — — 465 — 465 
Balance at March 31, 2021 $ 12,655 $13 $244,117 $(382)$(202,773)$40,975 
Net loss— — — — — — (1,273)(1,273)
Stock-based compensation expense— — — — 519 — — 519 
Foreign currency translation adjustments— — — — — (125)— (125)
Balance at June 30, 2021— $— 12,655 $13 $244,636 $(507)$(204,046)$40,096 

The accompanying notes are an integral part of these condensed consolidated financial statements



Table of Contents
Ekso Bionics Holdings, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
 Six Months Ended June 30,
 20222021
Operating activities:  
Net loss$(7,598)$(4,943)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization462 502 
Changes in allowance for doubtful accounts(7)48 
Gain on forgiveness of note payable (1,099)
Gain on revaluation of warrant liabilities(899)(886)
Stock-based compensation expense1,081 875 
Common stock contribution to 401(k) plan103 107 
Unrealized loss on foreign currency transactions972 372 
Changes in operating assets and liabilities:
Accounts receivable1,228 420 
Inventories(1,221)(136)
Prepaid expenses, and other assets, current and noncurrent(318)(135)
Accounts payable(1,048)(73)
Accrued, lease and other liabilities(836)(304)
Deferred revenues(373)(354)
Net cash used in operating activities(8,454)(5,606)
Financing activities:
Proceeds from issuance of common stock and warrants, net 37,295 
Proceeds from exercise of warrants 1,417 
Net cash provided by financing activities 38,712 
Effect of exchange rate changes on cash(40)(30)
Net (decrease) increase in cash(8,494)33,076 
Cash at beginning of period40,406 12,862 
Cash at end of period$31,912 $45,938 
Supplemental disclosure of cash flow activities
Cash paid for interest$55 $46 
Cash paid for income taxes$4 $ 
Supplemental disclosure of non-cash activities
Fair value of warrants issued upon equity financing$ $1,936 
Reclassification of warrant liability to equity upon exercise of warrants$ $2,461 
Transfer of inventory to property and equipment$175 $162 
Initial recognition of operating lease liability and right of use asset$174 $— 
Share issuance for common stock contribution to 401(k) plan$176 $152 
 
The accompanying notes are an integral part of these condensed consolidated financial statements


Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)

1.    Organization
 
Description of Business
 
Ekso Bionics Holdings, Inc. (the “Company”) designs, develops, and markets exoskeleton products to augment human strength, endurance and mobility. The Company’s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and by persons with physical disabilities. The Company has marketed devices that (i) enable individuals with neurological conditions affecting gait, including acquired brain injury ("ABI") and multiple sclerosis ("MS"), and spinal cord injury ("SCI"), to rehabilitate and to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods. Founded in 2005, the Company is headquartered in the San Francisco Bay area and listed on the Nasdaq Capital Market under the symbol “EKSO”.
 
Liquidity and Capital Resources
 
As of June 30, 2022, the Company had an accumulated deficit of $216,465.  Largely as a result of significant research and development activities related to the development of the Company’s advanced technology and commercialization of such technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. In the six months ended June 30, 2022, the Company used $8,454 of cash in its operations. Cash on hand as of June 30, 2022 was $31,912.

As described in Note 8, Notes payable, net, borrowings under the Company’s secured term loan agreement with Pacific Western Bank have a liquidity covenant requiring minimum cash on hand equivalent to the current outstanding principal balance. As of June 30, 2022, $2,000 of cash must remain as restricted. After considering cash restrictions, effective unrestricted cash as of June 30, 2022 is approximately $29,912. With this unrestricted cash balance, the Company believes that it currently has sufficient cash to fund its operations beyond the look forward period of one year from the issuance of these condensed consolidated financial statements.
 
2.    Basis of Presentation and Summary of Significant Accounting Policies and Estimates
 
Basis of Presentation and Consolidation
 
The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 24, 2022.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2021, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein.

The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or any future periods.
 
The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation.

Reclassifications

During the second quarter ended June 30, 2022, the Company reclassified the amortization of operating lease right-of-use assets in its condensed consolidated statements of cash flows. Amounts amortized related to operating lease right-of-use assets have


Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
been reclassified to "Depreciation and amortization" from "Prepaid expenses, and other assets, current and noncurrent" as applicable. Accordingly, prior period amounts have been reclassified to conform to the current period presentation, in all material respects. These reclassifications did not affect changes in cash flow used in operating activities or net increase in cash for the six months ended June 30, 2021.

Use of Estimates
 
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.

Foreign Currency

The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss.

Inventory
 
Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first-in, first-out basis. Materials from vendors are received and recorded as raw materials. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress ("WIP"). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge within the consolidated statements of operations and comprehensive loss. The Company's estimate of write-downs for excess and obsolete inventory is based on a detailed analysis which includes on-hand inventory and purchase commitments in excess of forecasted demand. Subsequent disposals of inventories are recorded as a reduction of inventory.

Leases

The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received.

Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current.

Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.



Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Revenue Recognition

The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations. Revenue recognition is evaluated based on the following five steps: (i) identification of the contract with the customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not directly observable, judgment is made to estimate the selling price based on market conditions and entity-specific factors including cost plus analyses, features and functionality of the product and/or services, the geography of the Company’s customers, and type of the Company’s markets. Any discounts or other reductions to the transaction price are allocated proportionately to all performance obligations within the multiple-element arrangement. The Company periodically validates the stand-alone selling price for performance obligations by evaluating whether changes in the key assumptions used to determine the stand-alone selling prices will have a significant effect on the allocation of transaction price between multiple performance obligations.

The Company exercised judgement to determine that a product returns reserve was not required as historical returns activity have not been material.

Going Concern
 
The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern.
 
Concentration of Credit Risk and Other Risks and Uncertainties
 
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.

Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable as of June 30, 2022 and December 31, 2021. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.
 
At June 30, 2022, the Company had two customers (14% and 13%) with an accounts receivable balance totaling 10% or more of the Company’s total accounts receivable, as compared with zero customers at December 31, 2021.
 
During the three months ended June 30, 2022, the Company had three customers with sales of 10% or more of the Company’s total revenue (34%, 13%, and 11%), as compared with one customer in the three months ended June 30, 2021 (13%).



Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
During the six months ended June 30, 2022, the Company had one customer with sales of 10% or more of the Company’s total revenue (22%), as compared with one customer in the six months ended June 30, 2021 (11%).
 
Recent Accounting Pronouncements

In June 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2022-02, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. The update will be effective for the Company beginning in the first quarter of 2023. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its condensed consolidated financial statements and related disclosures.

In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity’s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective for the Company beginning in the first quarter of 2024 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. The Company does not expect the impact of adopting ASU 2020-06 to be material on its consolidated financial statements.



3.    Accumulated Other Comprehensive Income (Loss)
 
The Company's accumulated other comprehensive income (loss) consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments. The change in accumulated other comprehensive income (loss) presented on the condensed consolidated balance sheets for the six months ended June 30, 2022 and 2021, is reflected in the table below net of tax:
 Six Months Ended June 30,
20222021
Balance at beginning of period$(17)$(847)
Net unrealized gain on foreign currency translation851 340 
Balance at end of period$834 $(507)
 
4.    Fair Value Measurement
 
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following:
 
Level 1—Quoted prices in active markets for identical assets or liabilities. The Company considers a market to be active when transactions for the asset occur with sufficient frequency and volume to provide pricing information on an ongoing basis.


Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The valuation of Level 3 investments requires the use of significant management judgments or estimation.

The Company’s fair value hierarchies for its financial assets and liabilities, which require fair value measurement on a recurring basis are as follows:
 TotalLevel 1Level 2Level 3
June 30, 2022    
Liabilities    
Warrant liabilities$651 $ $ $651 
December 31, 2021
Liabilities
Warrant liabilities$1,550 $ $ $1,550 
 
The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities for the period ended June 30, 2022, which were measured at fair value on a recurring basis:
 Warrant Liability
Balance at December 31, 2021$1,550 
Gain on revaluation of warrants issued in connection with the February 2021, June 2020, December 2019 and May 2019 financings(899)
Balance at June 30, 2022$651 
 
Refer to Note 10. Capitalization and Equity Structure – Warrants for additional information regarding the valuation of warrants.
 
5.    Inventories
 
Inventories consisted of the following:
 June 30, 2022December 31, 2021
Raw materials$2,416 $2,061 
Work in progress585 145 
Finished goods273 36 
Inventories$3,274 $2,242 

6.    Revenue

The Company’s medical device segment (EksoHealth) revenue is primarily generated through the sale and subscription of the EksoNR, the sale of support and maintenance contracts (Ekso Care), and the sale of accessories for the EksoNR. In 2021, the Company moved to a customer subscription sales model and away from a rental sales model. Under the rental sales model, the Company offered customers a short-term rental arrangement of its products to help bridge to a capital purchase since customers typically have challenges in obtaining approvals for capital expenditures. Subscription sales arrangements, however, bypass the customer capital purchase process, are intended to renew annually, and provide a long-term revenue stream.
 


Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility for sales of the EksoNR, software and accessories. Ekso Care support and maintenance contracts extend coverage beyond the Company’s standard warranty agreements. The separately priced Ekso Care contracts range from 12 to 48 months. The Company receives payment at the inception of the contract and recognizes revenue evenly over the term of the contracts. Revenue from medical device subscriptions is recognized evenly over the initial contract term, typically over 12 to 24 months.

The Company’s industrial device segment (EksoWorks) revenue is generated through the sale of the upper body exoskeletons (EksoVest and the EVO) and the support arm (EksoZeroG). Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility.

At the end of the second quarter of 2022, the Company ceased commercialization of the ZeroG support arm and related products and accessories. The Company may continue to sell parts and accessories to existing ZeroG customers to deplete its current stock of ZeroG inventories, however, the Company does not expect any future revenues derived from the sale of the ZeroG product line to have a material contribution to EksoWorks segment revenues. Refer to Note 13 Commitment and Contingencies for further information regarding commitments and obligations related to the ZeroG product line.
 
Deferred Revenue
 
For the sale of its products, the Company recognizes revenue upon the transfer of control of products to its customers, typically upon shipment from its facilities. For the subscription of its products, the Company generally recognizes revenue over the subscription term commencing upon the completion of customer training. For service agreements, the Company generally invoices customers at the beginning of the coverage period and records revenue related to the billed amounts over time, equivalent to the coverage period of the maintenance and support contract.

Deferred revenue is comprised mainly of unearned revenue related to service agreement contracts (Ekso Care), but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service.
 
Deferred revenue consisted of the following:
June 30, 2022December 31, 2021
Deferred extended maintenance and support$2,237 $2,349 
Deferred royalties 280 
Deferred device and advances46 66 
Total deferred revenues2,283 2,695 
Less current portion(1,140)(1,220)
Deferred revenues, non-current$1,143 $1,475 
 
Deferred revenue activity consisted of the following for the six months ended June 30, 2022:
Beginning balance$2,695 
Deferral of revenue728 
Recognition of deferred revenue(1,140)
Ending balance$2,283 
 
As of June 30, 2022, the Company’s deferred revenue was $2,283. The Company expects to recognize approximately $665 of the deferred revenue during the remainder of 2022, $789 in 2023, and $829 thereafter.

In addition to deferred revenue, the Company has a non-cancellable backlog of $1,847 related to its contracts for subscription units with its customers. These subscription contracts typically have 12 to 24 month terms, and subscription income is recognized on a straight-line basis over the term of the contract.


Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)

In the six months ended June 30, 2022, the Company recognized revenue of $280 related to a $300 upfront royalty payment associated with a license and distribution agreement that expired. The unrecognized royalty balance of $280 was included in deferred revenue as of December 31, 2021.
 
As of June 30, 2022 and December 31, 2021, total accounts receivable, net of allowance for doubtful accounts, were $3,468 and $4,824, respectively, and are included in accounts receivable, net and other assets on the Company’s condensed consolidated balance sheets.
 
The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 90 days.
 
Disaggregation of revenue

The following table disaggregates the Company’s revenue by major source for the three months ended June 30, 2022:
 EksoHealthEksoWorksTotal
Device revenue$2,369 $163 $2,532 
Service and support489 — 489 
Subscriptions225 51 276 
Parts and other117 23 140 
Collaborative arrangements28 — 28 
 $3,228 $237 $3,465 
 
The following table disaggregates the Company’s revenue by major source for the six months ended June 30, 2022:


Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
 EksoHealthEksoWorksTotal
Device revenue$3,332 $472 $3,804 
Service and support956  956 
Subscriptions441 120 561 
Parts and other273 331 604 
Collaborative arrangements107  107 
 $5,109 $923 $6,032 

The following table disaggregates the Company’s revenue by major source for the three months ended June 30, 2021:
 EksoHealthEksoWorksTotal
Device revenue$1,090 $288 $1,378 
Service and support447 — 447 
Rentals and subscriptions185 52 237 
Parts and other140 149 
Collaborative arrangements— — — 
 $1,862 $349 $2,211 

The following table disaggregates the Company’s revenue by major source for the six months ended June 30, 2021:
 EksoHealthEksoWorksTotal
Device revenue$2,109 $386 $2,495 
Service and support935  935 
Rentals and subscriptions337 122 459 
Parts and other194 24 218 
Collaborative arrangements14  14 
 $3,589 $532 $4,121 

7.    Accrued Liabilities
 
Accrued liabilities consisted of the following:
June 30, 2022December 31, 2021
Salaries, benefits and related expenses$1,290 $2,015 
Device warranty205 195 
Other88 89 
Total$1,583 $2,299 
 
The current portion of the device warranty liability is classified as a component of accrued liabilities, while the long-term portion of the device warranty liability is classified as a component of other non-current liabilities in the condensed consolidated balance sheets. A reconciliation of the changes in the device warranty liability for the three and six months ended June 30, 2022 is as follows:


Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Three Months EndedSix Months Ended
June 30, 2022June 30, 2022
Balance at beginning of period$286 $270 
Additions for estimated future costs 56 132 
Incurred costs(67)(127)
Balance at end of period$275 $275 
Balance as of June 30, 2022
Current portion$205 
Long-term portion70 
Total$275 
 
8.    Notes Payable, net
 
PWB Term Loan

In August 2020, the Company entered into a new loan agreement (the "PWB Loan Agreement") with a lender, Pacific Western Bank, and received a loan in the principal amount of $2,000 (the "PWB Term Loan") that bears interest on the outstanding daily balance at a rate equal to the greater of: (a) 0.50% above the variable rate of interest announced by the lender as its “prime rate” then in effect; or (b) 4.50%. The PWB Loan Agreement created a first priority security interest with respect to substantially all assets of the Company, including proceeds of intellectual property, but expressly excluding intellectual property itself.

The Company is required to pay accrued interest on the current loan on the 13th day of each month through and including August 13, 2023. The principal balance of the PWB Term Loan matures on August 13, 2023, at which time all unpaid principal and accrued and unpaid interest shall be due and payable in full. The interest rate of the PWB Term Loan is subject to increase in the event of late payments and after occurrence of and during the continuation of an event of default. The Company may elect to prepay the PWB Term Loan at any time, in whole or in part, without penalty or premium.

The PWB Loan Agreement contains a liquidity covenant, which requires that the Company maintain unrestricted cash and cash equivalents in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least the outstanding balance of the PWB Term Loan, which was $2,000 as of June 30, 2022. On June 30, 2022, with cash on hand of $31,912, the Company was compliant with this liquidity covenant and all other covenants.

The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest rate of 4.95% and 4.83% for the three and six months ended June 30, 2022. The debt issuance costs are amortized to interest expense using the effective interest method over the life of the loan.

The following table presents scheduled principal payments of the Company’s PWB term loan as of June 30, 2022:


Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
PeriodAmount
Remainder of 2022$ 
20232,000 
Total principal payments2,000 
Less debt discount and issuance cost5 
Note payable, net$1,995 
 
Current portion$ 
Long-term portion1,995 
Note payable, net$1,995 

Paycheck Protection Program Loan

On April 20, 2020, the Company received an unsecured loan (the "PPP Loan") in the principal amount of $1,086 under the Paycheck Protection Program (the “PPP”) administered by the U.S. Small Business Administration (the "SBA"), pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), or the PPP loan. The PPP loan bore interest at 1.00% per annum, and matured two years after the date of initial disbursement. The terms of the PPP loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020, (the "PPP Flexibility Act"), which was enacted on June 5, 2020. The PPP loan was used for payroll costs, costs related to certain group health care benefits and insurance premiums, rent payments, utility payments and interest payments on other debt obligation that were incurred before February 15, 2020. Under the terms of the CARES Act and the PPP Flexibility Act, the Company could apply for and be granted forgiveness for all or a portion of loan granted under the PPP loan, with such forgiveness to be determined, subject to limitations (including where employees of the Company have been terminated and not re-hired by a certain date), based on the use of the loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The terms of any forgiveness were also subject to further requirements in regulations and guidelines adopted by the SBA.

On June 28, 2021, the Company received notification from the SBA that the Company’s forgiveness application of the PPP loan and accrued interest, totaling $1,099, was approved in full, and the Company had no further obligations related to the PPP loan. Accordingly, the Company recorded a gain on the forgiveness of the PPP loan as gain on forgiveness of note payable on the condensed consolidated statement of operations during the three months ended June 30, 2021.


9.    Lease Obligations

The Company maintained a five-year operating lease agreement for its headquarters and manufacturing facility in Richmond, California (the "Richmond Lease") which expired at the end of May 2022. As of June 30, 2022, the Company continued to maintain its tenancy at this location. Pursuant to the terms of the original lease agreement, the Company incurs monthly expenses equal to the most recent monthly lease payment under the now expired lease agreement and its allocable portion of common area maintenance costs plus a 25% mark-up.

In July 2022, the Company entered into an operating lease agreement for its new headquarters and manufacturing facility in San Rafael, California (the "San Rafael Lease") expiring in October 2026 with the option to renew for an additional three-year period at the prevailing market rate at the time of extension. The Company plans to relocate to its new headquarters and manufacturing facility to San Rafael in August 2022. Refer to Note 13. Commitments and Contingencies for further information regarding the amount of future obligations related to the Company's operating leases.

The Company maintained a five-year operating lease agreement for its European operations office in Hamburg, Germany, which was set to expire in July 2022. In February 2022, the Company executed a new lease agreement with the same landlord for a replacement office in Hamburg, Germany commencing May 1, 2022 and expiring June 30, 2025 with an option to renew for one five-year period. Upon the early termination of the previous lease agreement, it was agreed between the landlord and the Company that access to the previously leased office space would be revoked and the Company would be relieved of its payment obligations for the final two months of the lease term. Consequently, the Company removed the right of use asset and lease


Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
liability, $15 and $16 respectively, recorded in its Condensed Consolidated Financial Statements related to the original Hamburg tenancy.

The Company has determined that the new Hamburg lease agreement constitutes a lease under ASC 842 and estimates the lease term as May 2022 through June 2025. The option to extend for a five-year period lacks significant economic incentives and disincentives which would make exercise reasonably certain. Fixed lease payments for identified lease components over the identified term have been discounted at the Company's estimated incremental borrowing rate and are reflected in the condensed consolidated balance sheets under the captions Lease liabilities, current and Lease liabilities, and the corresponding right of use asset is reflected in the condensed consolidated balance sheets under the caption Right-of-use assets. Non-lease components, such as common area maintenance costs, are excluded from the lease liability calculation and expensed as incurred. The Company records a straight-line monthly rent expense for this lease equal to the sum of all fixed lease payments divided by the number of months in the lease term.
 
The Company’s future lease payments as of June 30, 2022, which are presented as Lease liabilities, current and Lease liabilities on the Company’s condensed consolidated balance sheets are as follows:
PeriodOperating Leases
Remainder of 2022$28 
2023 - 2025148 
Total lease payments176 
Less: imputed interest(11)
Present value of lease liabilities$165 
Weighted-average remaining lease term (in years)3.0
Weighted-average discount rate4.7 %

Lease expense under the Company’s operating leases was $86 and $132 for the three months ended June 30, 2022 and 2021, respectively, and $212 and $265 for the six months ended June 30, 2022 and 2021, respectively.

10.    Capitalization and Equity Structure

Summary
 
The Company’s authorized capital stock at June 30, 2022 and December 31, 2021 consisted of 141,429 shares of common stock and 10,000 shares of preferred stock. As of June 30, 2022 and December 31, 2021, there were 13,010 and 12,693, respectively, shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding.

Common Stock

February 2021 Offering

In February 2021, the Company entered into an amended and restated underwriting agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"), to sell 3,902 shares of the Company's common stock for a public price of $10.25 per share, for gross proceeds of $40,000 (the "February 2021 Offering"). The Company received net proceeds of $36,504 from the February 2021 Offering after deducting underwriting discounts, commissions and estimated offering expenses. Pursuant to the Underwriting Agreement, the Company issued, to certain designees of Wainwright, five year warrants (the “2021 Warrants”) to purchase shares of Common Stock in an amount equal to 7.0% of the aggregate number of shares sold in the February 2021 Offering, or 273 shares, at an exercise price of $12.81 per share.

At the Market Offering

In October 2020, the Company entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC (the "Agent"), under which the Company may issue and sell shares of its common stock, from time to


Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
time, to or through the Agent. The Company may offer and sell shares having an aggregate offering price of up to $7,500 under the registration statement and prospectus supplement filed with the SEC related to such offering. Under the ATM Agreement, shares of the Company's common stock may not be sold for a price lower than $6.75 per share. The Company did not sell any shares under the ATM agreement during the three and six months ended June 30, 2022. The Company did not sell any shares under the ATM Agreement during the three months ended June 30, 2021. During the six months ended June 30, 2021, the Company sold 78 shares of common stock at an average price of $10.72 for proceeds of $791, net of commissions and issuance costs. As of June 30, 2022, the Company has $6,668 available for future offerings under the prospectus filed with respect to the ATM Agreement.

Warrants
 
Warrants outstanding as of June 30, 2022 and December 31, 2021 were as follows:  
SourceExercise
Price
Term
(Years)
December 31, 2021IssuedExercisedJune 30, 2022
2021 Warrants$12.81 5273   273 
June 2020 Investor Warrants$5.18 5.5127   127 
June 2020 Placement Agent Warrants$5.64 539   39 
December 2019 Warrants$8.10 5556   556 
December 2019 Placement Agent Warrants$8.44 552   52 
May 2019 Warrants$3.52 5193   193 
 1,240   1,240 

During the six months ended June 30, 2021, the Company received net proceeds of $1,417 from the exercise of 358 warrants and issued 300 shares of common stock, respectively, as a result of those exercises. No warrants were exercised during the six months ended June 30, 2022.
 
2021 Warrants

In February 2021, the Company issued the 2021 Warrants, exercisable for up to 273 shares of the Company’s common stock at an exercise price of $12.81 per share. The 2021 Warrants were exercisable immediately, and will expire five years from the date of issuance, or on February 11, 2026.

In addition, the 2021 Warrants contain a cashless exercise provision, whereby, if, at the time a holder exercises its 2021 Warrants, a registration statement registering the issuance or the resale of the shares of common stock underlying the 2021 Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect to instead receive, upon such exercise (either in whole or in part), the net number of shares of the Company’s common stock determined according to a formula set forth in the 2021 Warrants. The 2021 Warrants will be automatically exercised on a cashless basis on their expiration date. The 2021 Warrants could also require payment of liquidated damages by the Company in the form of cash payments in the event of a failure by the Company to timely deliver shares of common stock upon exercise of such warrants.

The 2021 Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the 2021 Warrants, the Company or any successor entity will, at the option of a holder of a 2021 Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder’s 2021 Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s 2021 Warrant within five trading days after the notice of exercise by the holder of the put option. Because of this put-option provision, the 2021 Warrants are classified as a liability and are marked to market at each reporting date.



Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
The warrant liability related to the 2021 Warrants is measured at fair value upon issuance and at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the 2021 Warrants:
June 30, 2022December 31, 2021
Current share price$1.65 $2.65 
Conversion price$